VRTX
Vertex Pharmaceuticals
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About VRTX
Vertex Pharmaceuticals Incorporated
A company that develops therapies for the treatment of cystic fibrosis
50 Northern Avenue, Boston, Massachusetts 02210
Develop and create transformative drugs
Founded in 1989, Vertex Pharmaceuticals Incorporated is a global biotechnology company. The company is dedicated to the discovery, development, production and commercialization of small molecule drugs for serious diseases in the professional market. The company has partnerships with some of the world's largest pharmaceutical companies, leading non-profit disease research institutions, and many of the world's most renowned academic institutions. The company has two products: KALYDECO and INCIVEK.
Company Financials
EPS
VRTX has released its 2024 Q4 earnings. EPS was reported at 3.98, versus the expected 4.02, missing expectations. The chart below visualizes how VRTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VRTX has released its 2024 Q4 earnings report, with revenue of 2.91B, reflecting a YoY change of 15.66%, and net profit of 913.00M, showing a YoY change of -5.76%. The Sankey diagram below clearly presents VRTX’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
